Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CAP-IT Clear all

Conditions: Psilocybin
Interventions: Psilocybin, Methylphenidate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Inflammation; Muscle
Interventions: ESPO-572®, PCSO-524®; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Brain-derived Neurotrophic Factor (BDNF), Cognitive Function, Affect
Interventions: Whole Coffee Fruit Concentrate (WCFC), Nutrim; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alcohol Use Disorder, Bipolar Disorder, Schizoaffective Disorder Bipolar Type
Interventions: Placebo, Citicoline, Pregnenolone; Drug · Dietary Supplement
Lead sponsor: Sherwood Brown, MD, PhD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Dallas, Texas • Edinburg, Texas

Conditions: D008593
Interventions: Shatavari Root Extract, oral capsule; Dietary Supplement
Lead sponsor: Jacksonville University; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Transplant; Complication, Rejection
Interventions: Allosure, AlloMap; Diagnostic Test
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Nutrition, Fatty Acids, Omega-3, Cognition, Resilience, Psychological, Psychology, Military
Interventions: Phospholipid-bound omega-3 supplement, Placebo supplement; Dietary Supplement
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Not listed
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Fort Benning, Georgia • Bethesda, Maryland • Charleston, South Carolina

Conditions: Duchenne Muscular Dystrophy
Interventions: Eplerenone, Spironolactone; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 7 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Kansas City, Kansas + 3 more

Conditions: Breast Neoplasms
Interventions: SU011248, Chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 77
States / cities: Corona, California • Fullerton, California • Glendora, California + 59 more

Conditions: Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse
Interventions: Varenicline, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cocaine Dependence
Interventions: Adderall-ER, Topiramate, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions: Enzalutamide, Trastuzumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 16
States / cities: Anaheim, California • Los Angeles, California • San Francisco, California + 12 more

Conditions: Shoulder Pain, Chronic Pain, Musculoskeletal Injury
Interventions: Dry Needling, Sham Dry Needling; Device · Other
Lead sponsor: Army-Baylor University Doctoral Program in Physical Therapy; Other
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Common Variable Immunodeficiency, Interstitial Lung Disease Due to Systemic Disease
Interventions: Fisetin, Placebo; Drug
Lead sponsor: Avni Joshi; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: T-cell Acute Lymphoblastic Leukemia
Interventions: Daratumumab / Hyaluronidase Injection; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coal Workers' Pneumoconiosis (Complicated)
Interventions: Pirfenidone; Drug
Lead sponsor: Pulmonary Research of Abingdon, LLC; Other
Eligibility: 40 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Abingdon, Virginia

Conditions: Malaria, Vivax
Interventions: Tafenoquine 150 mg, Matched placebo 150mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Glendale, California • Overland Park, Kansas • Baltimore, Maryland

Conditions: Covid19
Interventions: mQFPD, organic brown rice; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • San Diego, California

Conditions: Fabry Disease
Interventions: Lucerastat; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Birmingham, Alabama • Oakland, California • Gainesville, Florida + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 26 more

Conditions: Type 2 Diabetes
Interventions: CRx Health, Chronicare; Other
Lead sponsor: QuiO; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Midland, Michigan

Conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions: Omega 3 Fatty Acid; Dietary Supplement
Lead sponsor: Marshall University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Cancer
Interventions: Afuresertib, Carfilzomib; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Ulcerative Colitis
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more

Search by objective public record fields.

Precision Functional Brain Mapping in Psilocybin

Effectiveness of Two Different Forms of Marine Oil on Indirect Markers of Muscle Damage and Soreness in Untrained Men

Whole Coffee Fruit Concentrate Pilot Study 1

Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders

Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women

Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.

Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's

Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Feasibility of Near-infrared Spectroscopy to Measure Cortical Pain Pathway (Brain) Activation During Dry Needling

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19

A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Chronicare for Type 2 Diabetes (Chronicare-T2D)

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis